Regulus

RGLS NASDAQ
1.150
-0.030
-2.54%
交易中 12:03 07/23 EDT
开盘
1.200
昨收
1.180
最高
1.215
最低
1.130
成交量
2.50万
成交均量(3M)
16.25万
52周最高
4.068
52周最低
0.8000
换手率
0.12%
市值
2,388.12万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Regulus RGLS股票价格,Regulus股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
展开 >

最近浏览

名称
价格
涨跌幅